Zepbound in 2026: What It Is, Who Qualifies, What It Costs

Anna

By the GLP-1 US editorial team
 ·  Last reviewed:
 ·  About our review process

Zepbound is Eli Lilly’s brand-name tirzepatide approved specifically for chronic weight management. It’s the same molecule as Mounjaro (the diabetes brand), just packaged and labeled for a different indication. This page covers what Zepbound is, who qualifies, what it costs in 2026 across every path, and where to go for the deeper how-to-get guide.

What Zepbound Is

Zepbound is FDA-approved tirzepatide for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity — high blood pressure, type 2 diabetes, high cholesterol, sleep apnea, or cardiovascular disease.

It’s a weekly subcutaneous injection. The dose ladder runs 2.5, 5, 7.5, 10, 12.5, and 15 mg. Most patients start at 2.5 mg for 4 weeks, escalate to 5 mg, then continue titrating based on tolerability and weight loss response.

Approved by the FDA in November 2023. As of 2026 it’s the only dual GIP/GLP-1 receptor agonist with a chronic-weight-management label, which matters because SURMOUNT-5 (the head-to-head trial against semaglutide) showed Zepbound producing ~21% body-weight reduction versus ~14% for Wegovy over 72 weeks.

For how Zepbound fits inside the broader GLP-1 medication class, or how it compares to the underlying tirzepatide molecule including the diabetes label and compounded versions, the linked guides go deeper.

Who Qualifies

The FDA label requires one of:

  • BMI of 30 or higher (obesity), OR
  • BMI of 27 or higher (overweight) plus at least one weight-related comorbidity

Most insurance plans that cover Zepbound mirror these requirements with prior authorization paperwork. Your clinician submits BMI, comorbidity documentation, and (often) failed prior weight-loss attempts. About 40% of commercial plans cover Zepbound in 2026; coverage broke open through 2024–2025 but is still patchier than Wegovy coverage.

If you don’t have a covered plan, you have other routes — outlined below.

What Zepbound Costs in 2026

This is where most patients get tripped up because the price ladder is non-obvious.

Path Monthly cost Catch
Insurance with coverage $0–$50 copay PA paperwork + BMI/comorbidity gates
LillyDirect Self-Pay (2.5 mg vial) $349 Single-dose vials only
LillyDirect Self-Pay (5 mg vial) $499 Single-dose vials only
LillyDirect (7.5–15 mg vials) $599–$699 Higher doses, vial-only
Retail pharmacy without insurance $1,080+ List price for the pen; rarely the right path
GoodRx + retail ~$1,000 Marginal discount, still expensive
Compounded tirzepatide (different drug technically — see below) $149–$399 Not Zepbound. Same molecule, different supply chain

LillyDirect is Eli Lilly’s direct-to-patient program. It ships single-dose vials (not the auto-injector pen) directly to you and bypasses pharmacy markups. It has a 45-day refill rule — you can’t reorder before day 45, so plan your timing.

Compounded tirzepatide is not Zepbound — it’s the same molecule made by a compounding pharmacy rather than Lilly. It’s cash-pay only and significantly cheaper. The cheapest tirzepatide programs guide ranks the providers we vetted as patients; the best compounded GLP-1 providers overview covers safety considerations.

How to Get Zepbound

The short version of the three paths:

  1. Insurance + your existing doctor. Bring your BMI numbers, comorbidity history, and prior weight loss attempts. PA paperwork is standard.
  2. LillyDirect. Online intake, $349/month for the 2.5 mg vial. Lilly verifies you’re a U.S. resident with a valid prescription.
  3. Telehealth program. Most prescribe compounded tirzepatide (cheaper, not Zepbound-branded) but a few help with Zepbound PA appeals if you’ve been denied.

For the full breakdown — insurance appeal scripts, LillyDirect’s 45-day refill trap, what to do when your PA gets denied, and which telehealth programs help with Zepbound specifically — see how to get Zepbound.

What to Watch For

The 45-day refill rule on LillyDirect catches a lot of patients. If you ship your first month on day 1, the system won’t let you reorder until day 45 — meaning you’ll have a 14-day gap with no medication. Either order early and stockpile a refill, or know the timing going in.

Insurance step therapy. Some plans require you to fail Wegovy or Saxenda before they’ll cover Zepbound. Read your formulary’s specific step-therapy requirements before you appeal.

Compounded vs Zepbound aren’t interchangeable for insurance. If you’ve been getting compounded tirzepatide and want to switch to insurance-covered Zepbound, you’re starting the PA process from scratch. Insurers don’t care that you’ve been on the molecule already.

Side effects. Nausea (most common), constipation, fatigue, diarrhea, mild injection-site reactions for the first 4–8 weeks. Severe GI side effects affect ~5–10% of patients and may force a dose pause or discontinuation.

Where Next